专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007136615A2 COMBINATION CANCER THERAPY 审中-公开
标题翻译：组合癌症治疗
公开(公告)号：WO2007136615A2
公开(公告)日：2007-11-29
申请号：PCT/US2007/011595
申请日：2007-05-15
申请人： MERCK & CO., INC. , BANYU PHARMACEUTICAL CO., LTD. , VERTEX PHARMACEUTICALS INCORPORATED , BUSER-DOEPNER, Carolyn, A. , BLOECHER, Andrew, M. , FREEDMAN, Steven, J. , HARDING, Matthew, W. , HASAKO, Shinichi , HOOVER, Russell, R. , SHIMOMURA, Toshiyasu
发明人： BLOECHER, Andrew, M. , FREEDMAN, Steven, J. , HARDING, Matthew, W. , HASAKO, Shinichi , HOOVER, Russell, R. , SHIMOMURA, Toshiyasu
IPC分类号： A61K31/506
CPC分类号： A61K31/506 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of an Aurora kinase inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the Aurora kinase inhibitor and the anti-cancer agent may be additive or synergistic.
摘要翻译：本发明涉及在有需要的受试者中治疗癌症的方法，通过在有需要的受试者中施用第一量的极光激酶抑制剂或其药学上可接受的盐或水合物，在第一种治疗方法中，和第二量的抗癌剂。第一和第二量一起包括治疗有效量。 Aurora激酶抑制剂和抗癌剂的作用可能是相加或协同的。

2. 发明申请

WO2002028409A3 EFFECTS OF COMBINED ADMINISTRATION OF FARNESYL TRANSFERASE INHIBITORS AND SIGNAL TRANSDUCTION INHIBITORS 审中-公开
公开(公告)号：WO2002028409A3
公开(公告)日：2002-04-11
申请号：PCT/US2001/031104
申请日：2001-10-04
申请人： WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH , DALEY, George, Q. , HOOVER, Russell, R.
发明人： DALEY, George, Q. , HOOVER, Russell, R.
IPC分类号： A61K45/06
摘要： The present invention relates to methods of reducing proliferation of cells, enhancing apoptosis of cells or both in an individual in need thereof, comprising administering to the individual a combination of at least one farnesyl transferase inhibitor (FTI), such as an inhibitor or Ras function, and at least one signal transduction inhibitor (STI) in a therapeutically effective amount, wherein proliferation of cells is reduced and/or apoptosis of cells in enhanced in the individual. In one embodiment, the invention relates to a method of reducing proliferation of STI resistants cells, enhancing apoptosis of STI resistant cells, or both in an individual in need thereof, comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amount, wherein proliferation of STI resistant cells is reduced and/or apoptosis of STI resistant cells is enhanced in the individual. The present invention can be used to treat leukemia (e.g., CML) in an individual comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amount.

3. 发明申请

WO0228409A2 EFFECTS OF COMBINED ADMINISTRATION OF FARNESYL TRANSFERASE INHIBITORS AND SIGNAL TRANSDUCTION INHIBITORS 审中-公开
标题翻译：呋喃葡萄糖转运酶抑制剂和信号转导抑制剂组合管理的影响
公开(公告)号：WO0228409A2
公开(公告)日：2002-04-11
申请号：PCT/US0131104
申请日：2001-10-04
申请人： WHITEHEAD BIOMEDICAL INST , DALEY GEORGE Q , HOOVER RUSSELL R
发明人： DALEY GEORGE Q , HOOVER RUSSELL R
IPC分类号： A61K31/473 , A61K31/495 , A61K45/06 , A61P35/02 , A61K38/00
CPC分类号： A61K45/06 , A61K31/473 , A61K31/495 , A61K31/435 , A61K2300/00
摘要： The present invention relates to methods of reducing proliferation of cells, enhancing apoptosis of cells or both in an individual in need thereof, comprising administering to the individual a combination of at least one farnesyl transferase inhibitor (FTI), such as an inhibitor or Ras function, and at least one signal transduction inhibitor (STI) in a therapeutically effective amount, wherein proliferation of cells is reduced and/or apoptosis of cells in enhanced in the individual. In one embodiment, the invention relates to a method of reducing proliferation of STI resistants cells, enhancing apoptosis of STI resistant cells, or both in an individual in need thereof, comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amount, wherein proliferation of STI resistant cells is reduced and/or apoptosis of STI resistant cells is enhanced in the individual. The present invention can be used to treat leukemia (e.g., CML) in an individual comprising administering to the individual a combination of at least one FTI and at least one STI in a therapeutically effective amount.
摘要翻译：本发明涉及在有需要的个体中减少细胞增殖，增强细胞凋亡或二者的方法，包括向个体施用至少一种法呢基转移酶抑制剂（FTI）如抑制剂或Ras功能的组合和至少一种治疗有效量的信号转导抑制剂（STI），其中细胞增殖被减少和/或个体增强的细胞凋亡。在一个实施方案中，本发明涉及减少STI抗性细胞增殖的方法，增强STI耐药细胞的凋亡或两者在有需要的个体中的方法，包括向个体施用至少一种FTI和至少一种FTI的组合 STI在治疗有效量中，其中STI耐药细胞的增殖减少，和/或STI抗性细胞的细胞凋亡在个体中增强。本发明可用于治疗个体中的白血病（例如CML），其包括向个体施用治疗有效量的至少一种FTI和至少一种STI的组合。

4. 发明申请

WO2007136615A3 COMBINATION CANCER THERAPY 审中-公开
标题翻译：组合癌症治疗
公开(公告)号：WO2007136615A3
公开(公告)日：2008-07-24
申请号：PCT/US2007011595
申请日：2007-05-15
申请人： MERCK & CO INC , BANYU PHARMA CO LTD , VERTEX PHARMA , BUSER DOEPNER CAROLYN A , BLOECHER ANDREW M , FREEDMAN STEVEN J , HARDING MATTHEW W , HASAKO SHINICHI , HOOVER RUSSELL R , SHIMOMURA TOSHIYASU
发明人： BLOECHER ANDREW M , FREEDMAN STEVEN J , HARDING MATTHEW W , HASAKO SHINICHI , HOOVER RUSSELL R , SHIMOMURA TOSHIYASU
IPC分类号： A61K31/506
CPC分类号： A61K31/506 , A61K31/555 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of an Aurora kinase inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the Aurora kinase inhibitor and the anti-cancer agent may be additive or synergistic.
摘要翻译：本发明涉及在有需要的受试者中治疗癌症的方法，通过在有需要的受试者中施用第一量的极光激酶抑制剂或其药学上可接受的盐或水合物，在第一种治疗方法中，和第二量的抗癌剂。第一和第二量一起包括治疗有效量。 Aurora激酶抑制剂和抗癌剂的作用可能是相加或协同的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式